Skip to main content

Advertisement

Table 1 Comparison of pharmacokinetic parameters of echinocandins in patients receiving and not receiving continuous renal replacement therapy

From: Treatment with echinocandins during continuous renal replacement therapy

  Pharmacokinetic parameter
   Cmax, μg/mL AUC0-24h, μg·hour/mL t1/2, hours CLT Vd
PK studies in patients not receiving CRRT Caspofungin [69]a 12.04 96.01 9.29 0.59 L/hour N/A
Anidulafungin [70]b 7.2 110.3 24-26 1.0 L/hour 34.5 L
Micafungin [71]c 7.1 59.9 13.0 1.25 L/hour 23.0 L
PK studies in patients receiving CRRT Weiler et al. [42]d      
  Single doses (CVVHF) 8.4 91 11.7 7.8 mL/hour per kg 138 mL/kg
  Single doses (CVVHD) 8.2 76 12.4 9.8 mL/hour per kg 175 mL/kg
  Single doses in patients not receiving CRRT 7.3 58 9.5 10.8 mL/hour per kg 135 mL/kg
  Steady-state (CVVHF) 11.0 107 12.4 5.3 mL/hour per kg 97 mL/kg
  Steady-state (CVVHD) 10.8 141 15.2 4.2 mL/hour per kg 89 mL/kg
  Steady-state in patients not receiving CRRT 8.8 100 12.6 4.9 mL/hour per kg 104 mL/kg
Leitner et al. [36]e 8.5 109.9 28.8 NR 42 L
De Rosa et al. [72]f 5.68-9.04 67.48-98.18 15.34-31.99 1.48-2.6 L/hour 32.81-48.48 L
Kishino et al. [73]g 6.31 50.04 13.63 0.59 L/hour 11.53 L
Hirata et al. [43]h      
  Patients receiving CRRT N/A N/A N/A 1.4 L/hour 17.5 L
  Patients not receiving CRRT N/A N/A N/A 1.4 (L/hour 16.2 L
  1. Data are derived from different sources and trials and therefore are not always directly comparable. aPharmacokinetic data following single doses of 70 mg of caspofungin. bPharmacokinetic data following loading dose of 200 mg and maintenance dose of 100 mg of anidulafungin. cPharmacokinetic data following single doses of 100 mg of micafungin. dPharmacokinetics of caspofungin (single doses and steady-state) in critically ill patients on continuous venovenous hemofiltration (CVVHF), continuous venovenous hemodialysis (CVVHD), and control group not on continuous renal replacement therapy (CRRT). ePharmacokinetics of anidulafungin during CVVHF. fPharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVHF. gPharmacokinetics of 50 mg of micafungin (steady-state) in living donor liver recipients receiving CVVHF. hPharmacokinetics of micafungin (150-300 mg) in patients on continuous venovenous hemodiafiltration and not receiving CRRT. AUC0–24, area under the curve over 24-hour dosing interval; CLT, total clearance (L/h or mL/hour per kg); Cmax, maximum concentration; N/A, not available; NR, not reported; PK, pharmacokinetic; t1/2, elimination half-life; Vd, volume of distribution (L or mL/kg).